Molnupiravir 200 mg

DRUG2 trials

Sponsors

Ridgeback Biotherapeutics, LP, University of Witwatersrand, South Africa

Conditions

COVID-19SARS-CoV-2 Infection, COVID-19

Phase 2

Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19

CompletedNCT04405570

Ridgeback Biotherapeutics, LPSARS-CoV-2 Infection, COVID-19

Start: 2020-06-19End: 2021-02-21Updated: 2022-02-16

A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South Africa

CompletedNCT05459532

University of Witwatersrand, South AfricaCOVID-19

Start: 2022-08-12End: 2023-09-30Updated: 2025-07-01

Related Papers

Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates

UNC Libraries2022-11-24

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

The Lancet Infectious Diseases2022-10-1975 citations

Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates

Clinical Infectious Diseases2021-11-198 citations

Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent

Antibiotics2021-10-2385 citations

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.

2020-12-03308 citations